AQST

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change -0.04
Percentage change -1.13	%

Peers: APLS XOMA BPMC CRSP ASND ACRS MGNX MDGL GLPG GERN

| Held by: VTI IWM VXF DWAS IWN VTWO VFMO IWO IWC ITOT

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.45	Insider Own	14.88%	Shs Outstand	91.18M	Perf Week	-12.57%
Market Cap	344.37M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	-0.00%	Shs Float	77.61M	Perf Month	-24.31%
Income	-35.19M	PEG	-	EPS next Q	-0.13	Inst Own	45.89%	Short Float	13.08%	Perf Quarter	-21.96%
Sales	58.90M	P/S	5.85	EPS this Y	-234.62%	Inst Trans	18.97%	Short Ratio	6.84	Perf Half Y	36.35%
Book/sh	-0.50	P/B	-	EPS next Y	-29.31%	ROA	-41.55%	Short Interest	10.15M	Perf Year	90.75%
Cash/sh	0.85	P/C	4.42	EPS next 5Y	-	ROE	-	52W Range	1.84 - 6.23	Perf YTD	86.98%
Dividend Est.	-	P/FCF	-	EPS past 5Y	46.61%	ROI	-48.54%	52W High	-39.38%	Beta	2.66
Dividend TTM	-	Quick Ratio	5.91	Sales past 5Y	-4.81%	Gross Margin	69.39%	52W Low	105.27%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	6.37	EPS Y/Y TTM	-109.42%	Oper. Margin	-35.83%	RSI (14)	30.96	Volatility	5.91% 6.46%
Employees	135	Debt/Eq	-	Sales Y/Y TTM	22.56%	Profit Margin	-59.75%	Recom	1.12	Target Price	10.06
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-301.27%	Payout	-	Rel Volume	0.53	Prev Close	3.82
Sales Surprise	6.73%	EPS Surprise	-10.64%	Sales Q/Q	4.15%	Earnings	Nov 04 AMC	Avg Volume	1.48M	Price	3.78
SMA20	-15.62%	SMA50	-22.12%	SMA200	-6.85%	Trades		Volume	283,620	Change	-1.13%

Date	Action	Analyst	Rating Change	Price Target Change
May-10-24	Initiated	Leerink Partners	Outperform	$8
Apr-11-24	Initiated	Piper Sandler	Overweight	$10
Mar-28-24	Initiated	Raymond James	Outperform	$7
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$7
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy	$14
Aug-20-18	Initiated	RBC Capital Mkts	Outperform	$23
Aug-20-18	Initiated	JMP Securities	Mkt Outperform	$29

Dec-02-24 08:00AM	Aquestive Therapeutics Announces Positive FDA Feedback and Reaffirms NDA Submission Guidance for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire) -5.50%
Nov-16-24 01:25AM	Is Aquestive Therapeutics (AQST) the Best Multibagger Stock to Buy Heading into 2025? (Insider Monkey)
Nov-12-24 08:00AM	Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 02:07AM	Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Call Highlights: Navigating Growth Amidst ... (GuruFocus.com) +6.62%
Nov-04-24 07:00PM	Aquestive Therapeutics (AQST) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -6.70% -7.67%
05:50PM	Loading…
05:50PM	Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:48PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:36PM	Aquestive Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
07:11AM	Aquestive Therapeutics Inc (AQST) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Nov-01-24 09:07AM	Aquestive Therapeutics Inc (AQST) Q3 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Oct-25-24 08:29AM	Aquestive Therapeutics Breakthrough in Allergy Treatment Study (TipRanks)
08:00AM	Aquestive Therapeutics to Present Subsequent Analysis of Pivotal Study for Anaphylm (epinephrine) Sublingual Film Demonstrating Comparable PK and PD Data to Epinephrine Injection Regardless of Variable Placement or Intraoral Movement at American College of Allergy Asthma and Immunology (ACAAI) 2024 Annual Meeting (GlobeNewswire)
Oct-24-24 08:00AM	Aquestive Therapeutics Announces Positive Topline Results from Oral Allergy Syndrome (OAS) Challenge Study for Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Oct-21-24 08:00AM	Aquestive Therapeutics to Report Third Quarter 2024 Financial Results and Recent Business Highlights on November 4 and Host Conference Call on November 5 at 8:00 a.m. ET (GlobeNewswire)
Sep-30-24 02:25PM	Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate (Benzinga) +5.51%
08:30AM	Loading…
Sep-27-24 08:30AM	Aquestive Therapeutics Spotlights its Innovative Epinephrine Delivery Pipeline at Virtual Investor Day (GlobeNewswire) -5.60%
Sep-09-24 08:15AM	Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th (GlobeNewswire) +12.20%
Aug-22-24 08:00AM	Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -7.31%
Aug-14-24 08:00AM	Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm (GlobeNewswire)
Aug-06-24 06:30PM	Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:32PM	Aquestive Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:22PM	Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-25-24 08:00AM	Aquestive Therapeutics Reports Positive Topline Data for Anaphylm (epinephrine) Sublingual Film from Self-Administration Study (GlobeNewswire)
Jul-23-24 08:00AM	Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET (GlobeNewswire) +9.90%
Jun-27-24 08:00AM	Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism (GlobeNewswire) +7.02%
Jun-25-24 01:00PM	Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows (Benzinga)
08:00AM	Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Jun-18-24 08:00AM	Aquestive Therapeutics to Join the Russell 3000 and Russell 2000 Indexes Effective June 28, 2024 (GlobeNewswire)
Jun-03-24 08:00AM	Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities (GlobeNewswire)
08:00AM	Loading…
May-28-24 08:00AM	Aquestive Therapeutics to Present Anaphylm (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference (GlobeNewswire)
May-10-24 07:11AM	Leerink Partners Starts Aquestive Therapeutics With Outperform Rating, $8 Price Target (MT Newswires) -6.08%
May-09-24 04:51PM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2024 Earnings Call Transcript (Insider Monkey) +6.65%
08:00AM	Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference (GlobeNewswire)
03:05AM	Aquestive Therapeutics Inc (AQST) Q1 2024 Earnings Call Transcript Highlights: Navigating ... (GuruFocus.com)
May-07-24 09:57PM	AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -8.73%
07:00PM	Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics (Zacks)
05:25PM	Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:29PM	Aquestive Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:19PM	Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Apr-30-24 10:01AM	Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for (Zacks) -10.04%
Apr-29-24 11:19AM	Aquestive Therapeutics Obtains FDA Approval for Libervant to Treat Seizure in Children (MT Newswires) -8.23%
07:00AM	Aquestive Therapeutics Receives U.S. FDA Approval and Market Access for Libervant (diazepam) Buccal Film in Pediatric Patients Ages 2 to 5 and Provides Update on Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Apr-25-24 08:00AM	Aquestive Therapeutics to Report First Quarter 2024 Financial Results and Recent Business Highlights on May 7 and Host Conference Call on May 8 at 8:00 a.m. ET (GlobeNewswire)
Apr-17-24 08:00AM	Coming FDA Approvals Could Send These 3 Drug Stocks Soaring (InvestorPlace)
Apr-12-24 04:01PM	Aquestive Therapeutics to Present Crossover Study Data for Libervant (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology (GlobeNewswire)
Apr-02-24 06:15PM	Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note (Zacks) +5.80%
Apr-01-24 08:00AM	Aquestive Therapeutics Strengthens Board of Directors with Experienced Biotech Executive (GlobeNewswire)
Mar-25-24 08:00AM	Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock (GlobeNewswire)
Mar-22-24 06:00PM	Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know (Zacks)
Mar-20-24 08:46AM	Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today? (InvestorPlace) -15.64%
Mar-19-24 09:49PM	Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
05:00PM	Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 50,000 Shares of Aquestive ... (GuruFocus.com)
04:01PM	Aquestive Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Mar-18-24 11:47AM	Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals (Zacks) -9.52%
06:46AM	Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength? (Zacks)
Mar-15-24 01:00PM	5 Growth Stocks Under $50 for March 2024 (Investopedia) +16.00%
Mar-14-24 05:23PM	Aquestive Therapeutics Announces Pivotal Study for Anaphylm (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting (GlobeNewswire)
Mar-12-24 05:00PM	Insider Sell: Chief Innovation/Tech Officer Alexander Schobel Sells 25,000 Shares of Aquestive ... (GuruFocus.com) +6.67%
Mar-07-24 01:43PM	Aquestive Therapeutics Inc Reports Full Year 2023 Financial Results (GuruFocus.com) +12.92%
11:56AM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:53AM	Q4 2023 Aquestive Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-05-24 10:51PM	AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace) +20.05%
06:15PM	Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:15PM	Aquestive Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
05:05PM	Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-24 09:30AM	Wall Street Bulls Look Optimistic About Aquestive Therapeutics (AQST): Should You Buy? (Zacks)
Feb-29-24 06:00PM	Aquestive Therapeutics (AQST) Outperforms Broader Market: What You Need to Know (Zacks) +15.53%
Feb-21-24 10:27AM	Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect (Zacks) -5.28%
08:00AM	Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET (GlobeNewswire)
Feb-20-24 06:00PM	Aquestive Therapeutics (AQST) Registers a Bigger Fall Than the Market: Important Facts to Note (Zacks)
Feb-15-24 08:00AM	Aquestive Therapeutics to Present Anaphylm (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting (GlobeNewswire)
Feb-14-24 06:00PM	Aquestive Therapeutics (AQST) Rises Higher Than Market: Key Facts (Zacks)
Feb-08-24 06:00PM	Why Aquestive Therapeutics (AQST) Outpaced the Stock Market Today (Zacks)
Feb-02-24 06:00PM	Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why (Zacks)
Jan-30-24 08:00AM	Aquestive Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Conference (GlobeNewswire)
Jan-26-24 06:00PM	Aquestive Therapeutics (AQST) Increases Despite Market Slip: Here's What You Need to Know (Zacks)
Jan-23-24 06:15PM	Aquestive Therapeutics (AQST) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Jan-17-24 06:15PM	Aquestive Therapeutics (AQST) Declines More Than Market: Some Information for Investors (Zacks) -5.52%
Jan-11-24 06:15PM	Here's Why Aquestive Therapeutics (AQST) Fell More Than Broader Market (Zacks)
Jan-03-24 08:10AM	Here's Why You Should Invest in Aquestive (AQST) Stock Now (Zacks)
Dec-29-23 09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks)
Dec-13-23 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks) +5.05%
Dec-05-23 08:00AM	Aquestive Therapeutics Doses First Patient in Phase 3 Pivotal Clinical Study Evaluating Pharmacokinetics and Pharmacodynamics of Anaphylm (epinephrine) Sublingual Film (GlobeNewswire)
Nov-29-23 09:55AM	Aquestive Therapeutics (AQST) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Nov-27-23 12:00PM	Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should Know (Zacks) -8.49%
09:40AM	Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year? (Zacks)
Nov-16-23 12:00PM	Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.18%
Nov-10-23 09:40AM	Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year? (Zacks)
08:00AM	Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting (GlobeNewswire)
Nov-08-23 02:58PM	Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-06-23 05:55PM	Aquestive Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
05:54PM	Aquestive Therapeutics Inc (AQST) Reports 25% Year-Over-Year Growth in Year-to-Date Revenue (GuruFocus.com)
04:37PM	Aquestive Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Nov-02-23 08:00AM	Aquestive Therapeutics Completes $45 Million Debt Refinancing (GlobeNewswire) -6.49%
Nov-01-23 06:00PM	Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
Oct-31-23 08:00AM	Aquestive Therapeutics to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 6 and Host Conference Call on November 7 at 8:00 a.m. ET (GlobeNewswire)
Oct-24-23 06:00PM	Aquestive Therapeutics (AQST) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Oct-09-23 06:15PM	Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why (Zacks) +6.06%
08:00AM	Aquestive Therapeutics Provides Business Update (GlobeNewswire)

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients' therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jung Cassie	Chief Operating Officer	Nov 26 '24	Sale	4.87	44	214	0	Nov 27 04:24 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Mar 15 '24	Sale	6.00	50,000	300,000	984,476	Mar 19 02:30 PM
Schobel Alexander Mark	Chief Innovation/Tech Officer	Mar 08 '24	Sale	5.19	25,000	129,685	1,040,371	Mar 12 01:45 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Aquestive Therapeutics Inc

Upgrade your FINVIZ experience